SCHEMBL4708802

SCHEMBL4708802

O=S1(=O)c2cc(Cl)c(Cl)cc2Nc2cc(Cl)c(Cl)cc21

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.43
MEN1 O00255 2/20 0.43
NOX1 Q9Y5S8 1/20 0.43
CES1 P23141 1/20 0.39
KDM4E B2RXH2 3/20 0.37
MAPT P10636 2/20 0.37
POLB P06746 1/20 0.37
CA1 P00915 3/20 0.36
CA2 P00918 2/20 0.36
CA12 O43570 1/20 0.36
CA4 P22748 1/20 0.36
CA7 P43166 1/20 0.36
CA9 Q16790 1/20 0.36
LMNA P02545 4/20 0.34
TSHR P16473 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
ALDH1A1 P00352 3/20 0.34
CYP1A2 P05177 3/20 0.34
CYP3A4 P08684 2/20 0.34
THRB P10828 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9973591 0.79 AHR (0.35) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL4710463 0.71 KMT2A (0.43) KMT2AMEN1NOX1CES1KDM4E
SCHEMBL13398402 0.68
SCHEMBL18067724 0.67 CD44 (0.41) KMT2AMEN1LMNATSHRCYP3A4
SCHEMBL4706812 0.64 MAOA (0.42) MAPTCA2CA12CA4CA7
SCHEMBL31348058 0.64 KMT2A (0.50) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL3033333 0.64 KMT2A (0.50) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL10278599 0.63 CA1 (0.53) KMT2AMEN1NOX1KDM4EMAPT
SCHEMBL4706870 0.60 NOX1 (0.45) KMT2AMEN1NOX1CES1MAPT
SCHEMBL20664932 0.60 KMT2A (0.46) KMT2AMEN1NOX1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP claimed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP claimed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO claimed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US claimed
EP-1765797-A4 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIV KANSAS CT FOR RES INC (US) 2008-02-06 EP disclosed
EP-1765797-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE University of Kansas Center for Research, Inc. (US) 2007-03-28 EP disclosed
WO-2006002441-A1 PHENOTHIAZINE DERIVATIVES AND THEIR METHOD OF USE UNIVERSITY OF KANSAS (US) 2006-01-05 WO disclosed
US-20050288279-A1 Phenothiazine derivatives and their method of use KANSAS MEDICAL CENTER, UNIVERSITY OF 2005-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050288279-A1 Phenothiazine derivatives and their method of use SHBG, GPR119, BRDT KMT2A 1178/4885MEN1 2558/4885NOX1 3177/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.